

QIBA Process Committee Meeting

Tuesday, August 2, 2022, at 2 pm (CT)

Meeting Summary

Attendees:

Kevin O'Donnell, MASC (Chair)

Michael Boss, PhD (Vice Chair)

Caroline Chung, MD

Cathy Elsinger, PhD

Timothy Hall, PhD

Nancy Obuchowski, PhD

RSNA Staff:

Joe Koudelik

Susan Stanfa

Next Steps / Action Items:

- [Renaming of Profile Stage 3 Update on Survey](#)
 - Thirteen QIBA Steering Committee (SC) members responded to the survey and the following results breakdown was first shared with the Process Cmte during the July 5 meeting:
 - Clinically Feasible Profile – 6 votes
 - Field Tested Profile – 4 votes
 - Tested Consensus Profile – 3 votes
 - The SC approved the stage 3 name change to Clinically Feasible following a ranking exercise of possible names
 - Comments received during polls were shared with the Process Cmte on July 5
 - Transition plan to be developed and will include editor assignments
 - BC Profile editors to update their stage 3 Profile documents and staff to republish them on the QIBA Wiki
 - Staff to update informative overview QIBA Wiki pages
 - Mr. O'Donnell to update Process QIBA Wiki pages
 - This change will be discussed during the August 4 MR CC meeting, and it was suggested as a subtheme of the Nov. 30, 2022 QI Symposium sponsored by QIBA
- [Profile Maintenance/Versioning/Naming](#)
 - Tabled until next the next PC meeting on August 16
- [Profile Editors to Discuss Streamlined Profile Template](#)
 - Feedback on the new Profile template will be reviewed during Profile Editor calls
 - Profile Editor group to be composed of 4-5 editors of Profiles at various stages across modalities
 - Dr. Boss to reach out to DCE-MRI, fMRI, CEUS BC leaders via email and identify one additional prospective group member
 - Consensus (Stage 2) Profile authors welcome to participate and provide feedback
 - Streamlined Profile Template to be updated based on Profile editor feedback
 - Staff to schedule meeting as soon as attendees are confirmed
- [Estimates of Precision Guidance Text](#)
 - Document provides guidance on drafting assessment procedures for Profiles at Stage 3 (Clinically Feasible) and Stage 4 (Claim Confirmed) to test:
 - the conformance of an actor, and
 - the composite performance of a site (e.g., to compare against the performance described in the Claim itself)
 - In Stage 3, Claims assumptions underlying the claims have not yet been tested and so they are hypotheses, but if sites want to meet Claim, they need to follow a set of requirements
 - This document describes the conformance testing required to show that the assumptions underlying the claims in a Stage 3 Profile are met at a specific site

- In contrast, Profiles that have achieved Stage 4 contain claims that have been verified in a multi-site, multi-vendor study
 - Minimum number of vendor systems tested per site still needs to be determined
 - Conformance testing of the assumptions underlying the claim is required at Stage 4 and takes the form of tests of non-inferiority with the claimed precision and bias
 - This document describes the conformance testing required to show that the assumptions underlying the claims in a Stage 4 profile are met at a specific site or by a specific actor
 - Sites to test whether they meet Profile requirements rather than whether they meet the Claim (while multi-center trials are not required, a test-retest study on a small subset is required)
 - Further discussion needed on minimum requirements of Stage 4 study design
 - Mr. O'Donnell to review introduction and revise language
 - Document to be distributed for PC member feedback
- Agenda for the next meeting on Aug. 16 can be found on the [Process Cmte page](#) of the QIBA Wiki

Next Process Committee Meeting: Tuesday, August 16, 2022, at 2 p.m. (CT) [1st & 3rd Tuesdays]

Zoom link: <https://rsna-org.zoom.us/j/89877175730?pwd=V282c2FPSU1vdDhWejRSGZYZTVZdz09>

Meeting ID: 898 7717 5730

Passcode: Process